Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe
PERiPLEX®
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, has announced that it has signed agreements with medical technology companies, Medisur and Peripal AG to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Both companies are specialists in the development and distribution of products which enable patient self-management and will supply PERiPLEX as part of a highly complementary product portfolio in key European markets including France, Germany, Italy, The Netherlands, Austria and Switzerland.
PD is becoming widely accepted as a preferred method for managing end-stage renal disease as it offers greater patient mobility and independence compared to other dialysis options, as well as being gentler to residual kidney function in early-stage disease. Recurring infection, or peritonitis, is a major issue for PD patients especially as there is no effective diagnostic test that can provide early indication of infection. Using current methods, diagnosis of infection can take more than 24 hours, which risks damage to the peritoneal membrane, or the formation of scar tissue, preventing long-term use of PD.
PERiPLEX detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 10 minutes. A positive result can give PD patients warning of an infection, prompting them to contact their healthcare provider to initiate antibiotic therapy. Earlier identification of infection would enable pre-emptive use of available antibiotics, resulting in improved management of infection and prevention of infection-related damage to the peritoneal membrane.
Mark Davis, co-founder and CEO at Mologic commented: “Establishing a global distribution network is integral to Mologic’s product commercialisation strategy. With the appointment of distributors across Europe we will ensure PERiPLEX is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home. Medisur and Peripal share our mission to improve the lives of patients by bringing diagnostics and treatment closer to home, and with highly complementary product portfolios, we look forward to working together.”
The PERiPLEX technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).
PD is becoming widely accepted as a preferred method for managing end-stage renal disease as it offers greater patient mobility and independence compared to other dialysis options, as well as being gentler to residual kidney function in early-stage disease. Recurring infection, or peritonitis, is a major issue for PD patients especially as there is no effective diagnostic test that can provide early indication of infection. Using current methods, diagnosis of infection can take more than 24 hours, which risks damage to the peritoneal membrane, or the formation of scar tissue, preventing long-term use of PD.
PERiPLEX detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 10 minutes. A positive result can give PD patients warning of an infection, prompting them to contact their healthcare provider to initiate antibiotic therapy. Earlier identification of infection would enable pre-emptive use of available antibiotics, resulting in improved management of infection and prevention of infection-related damage to the peritoneal membrane.
Mark Davis, co-founder and CEO at Mologic commented: “Establishing a global distribution network is integral to Mologic’s product commercialisation strategy. With the appointment of distributors across Europe we will ensure PERiPLEX is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home. Medisur and Peripal share our mission to improve the lives of patients by bringing diagnostics and treatment closer to home, and with highly complementary product portfolios, we look forward to working together.”
The PERiPLEX technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).
